FDA warns clinical investigator Daniel C. Tarquinio over enrolling ineligible subjects in investigational drug trials.
What happened
FDA inspected the clinical site from October 18 and November 5, 2021, under its program for inspecting clinical research and reviewed the investigator’s response to inspection findings. FDA found that four subjects were enrolled in an investigational drug protocol and then an open-label extension even though each was already enrolled and participating in another clinical study, contrary to the investigational plans’ exclusion criteria.
What FDA found
Failed to ensure the clinical investigation was conducted according to the investigational plan.
21 CFR 312.60Enrolled subjects who did not meet eligibility criteria because they were already participating in another clinical study.
21 CFR 312.60
What FDA wants
Within 15 business days, notify FDA in writing of actions taken to prevent similar violations. FDA also tells the investigator to address the deficiencies and ensure ongoing or future studies comply with FDA regulations.
Who should pay attention
- clinical research sites
- sponsors and contract research organizations running trials
- IRBs overseeing enrollment
This is a summary. Read the original letter on fda.gov.